drugset
drugset / Trial / NCT02214901

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers

NCT02214901 ↗

Phase 1 Completed 91 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety, tolerability, and pharmacokinetics of BIBW 2948 BS

Timeline

Start
2005-03
Primary completion
2005-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBW 2948 BS Unknown 0.75 mg Inhaled
Subject BIBW 2948 BS Unknown 150 mg Inhaled

Indications

No indication recorded.